RxDoctor Payments Data

Kristine Crouch

Family · Henderson, NVNPI 1699490748

Payments from drug & device makers

$1,368in general payments, 2019–2025

Across 71 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$215
  • Astellas Pharma US Inc$183
  • AbbVie$168
  • Boehringer Ingelheim$134
  • Novo Nordisk$127
  • Novartis$82
  • plus $459 from 13 others

What the payments were for

  • Food & beverage$1,30295%
  • Education$665%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,368 in reported general payments places this provider in the 75th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$143,001
Medicare patients
405
Services billed
2,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$125,913
MounjaroTirzepatide73$98,310
OzempicSemaglutide42$62,991
JardianceEmpagliflozin34$46,595
RybelsusSemaglutide24$31,266
FarxigaDapagliflozin Propanediol24$28,793
Breo ElliptaFluticasone/Vilanterol20$9,569
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,538
PremarinEstrogens, Conjugated13$6,978
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen253$5,809
Novolog FlexpenInsulin Aspart15$4,121
Atorvastatin Calcium441$3,301
Gabapentin209$3,152
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,143
SymbicortBudesonide/Formoterol Fumarate13$2,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$30$132,891109 claims
Lilly USA, LLCMounjaro$215$98,31073 claims
Novo NordiskOzempic, Rybelsus$127$94,25766 claims
Boehringer IngelheimJardiance$134$46,59534 claims
AstraZenecaFarxiga, Symbicort$66$31,61637 claims
GSKBreo Ellipta, Trelegy Ellipta$17$19,10735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,501 family providers in Nevada.

Other family in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →